High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.
Journal Information
Full Title: J Immunother Cancer
Abbreviation: J Immunother Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests: The conference on which this manuscript was based was sponsored by Prometheus. HLK, DJS, AAT, SSA and MBA were consultants for this conference. JNL is an employee of Prometheus Laboratories Inc. JPD is a consultant and on the speaker's bureau for Prometheus."
Funding Disclosure
Evidence found in paper:
"Competing interests: The conference on which this manuscript was based was sponsored by Prometheus. HLK, DJS, AAT, SSA and MBA were consultants for this conference. JNL is an employee of Prometheus Laboratories Inc. JPD is a consultant and on the speaker's bureau for Prometheus."
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025